Canine prostatic carcinoma (PCa) is considered a relevant model for studying advanced, hormone refractory PCa in men. It has been proposed that cancer contains a minor population of cells that can selfrenew while simultaneously giving rise to tumour cells (cancer stem cells). Survivin is an acknowledged cancer therapy-resistance factor overexpressed in several tumour types, proposed as a valid cancer biomarker for human prostatic cancer for an early screening for malignancy. Sox9 is a stem cell marker expressed in several adult tissues, required for prostate development. Accumulating evidence indicates that it contributes to the development of human PCa. No studies have been published concerning the immunolocalization of survivin and Sox9 in canine prostatic hyperplasia (BPH) and neoplasia.AIM: to evaluate the patterns and levels of expression of survivin and Sox9 in canine BPH and PCa, in order to correlate their expression with malignant histological features. immunhistochemistry with specific antibodies in a set of canine BPH and PCa. Survivin nuclear and rare cytoplasmic immunostaining were present among the basal/reserve cell layer of normal and hyperplastic prostatic lobules. An increase of survivin expression was observed in PCas compared with BPHs. 6/11 PCas showed rare positive nuclei, mainly among the “basaloid” neoplastic cells in the areas with a tubular-papillary arrangement. In the areas with a solid pattern the cytoplasmic immunostaining was more diffuse. Sox9 expression was absent in normal prostatic glands and in all BPHs. 6/9 cases of PCa were highly positive. Based on the role of survivin as a stem cell marker and the main role in proliferation of nuclear survivin, the positive cells among basal cell layer in normal and HBP cases could represent transit amplifying cells maintaining some stem cell proprieties. The increased survivin expression in Pcas would indicates the molecule as a valid prognostic marker. The absence of expression of Sox9 in the normal gland and all the BPHs suggests that Sox9 is not a stem cell marker of canine adult prostatic stem cells. The high expression observed in PCas clearly suggests an important role of the molecule in canine prostatic carcinogenesis and malignant progression. Further studies should be done in order to confirm this hypothesis.
Bongiovanni L, Caposano F, Ciccarelli A, Romanucci M, Malatesta D, Benazzi C, et al. (2014). STEM CELL MARKERS IN BENIGN AND MALIGNANT CANINE PROSTATE TISSUES: AN IMMUNOHISTOCHEMICAL INVESTIGATION.
STEM CELL MARKERS IN BENIGN AND MALIGNANT CANINE PROSTATE TISSUES: AN IMMUNOHISTOCHEMICAL INVESTIGATION
BENAZZI, CINZIA;
2014
Abstract
Canine prostatic carcinoma (PCa) is considered a relevant model for studying advanced, hormone refractory PCa in men. It has been proposed that cancer contains a minor population of cells that can selfrenew while simultaneously giving rise to tumour cells (cancer stem cells). Survivin is an acknowledged cancer therapy-resistance factor overexpressed in several tumour types, proposed as a valid cancer biomarker for human prostatic cancer for an early screening for malignancy. Sox9 is a stem cell marker expressed in several adult tissues, required for prostate development. Accumulating evidence indicates that it contributes to the development of human PCa. No studies have been published concerning the immunolocalization of survivin and Sox9 in canine prostatic hyperplasia (BPH) and neoplasia.AIM: to evaluate the patterns and levels of expression of survivin and Sox9 in canine BPH and PCa, in order to correlate their expression with malignant histological features. immunhistochemistry with specific antibodies in a set of canine BPH and PCa. Survivin nuclear and rare cytoplasmic immunostaining were present among the basal/reserve cell layer of normal and hyperplastic prostatic lobules. An increase of survivin expression was observed in PCas compared with BPHs. 6/11 PCas showed rare positive nuclei, mainly among the “basaloid” neoplastic cells in the areas with a tubular-papillary arrangement. In the areas with a solid pattern the cytoplasmic immunostaining was more diffuse. Sox9 expression was absent in normal prostatic glands and in all BPHs. 6/9 cases of PCa were highly positive. Based on the role of survivin as a stem cell marker and the main role in proliferation of nuclear survivin, the positive cells among basal cell layer in normal and HBP cases could represent transit amplifying cells maintaining some stem cell proprieties. The increased survivin expression in Pcas would indicates the molecule as a valid prognostic marker. The absence of expression of Sox9 in the normal gland and all the BPHs suggests that Sox9 is not a stem cell marker of canine adult prostatic stem cells. The high expression observed in PCas clearly suggests an important role of the molecule in canine prostatic carcinogenesis and malignant progression. Further studies should be done in order to confirm this hypothesis.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
